[ad_1]
With the intensification of the epidemic and the reduction of hospital capacity, it is increasingly important that patients receive drugs containing favipiravir as soon as possible after the onset of symptoms of viral infection, including in primary care – Miklós Keserű nak. Miklós György Keserű, Head of the Pharmaceutical Chemistry Research Group at the Natural Sciences Research Center, highlighted:
- favipiravir, taken as a tablet, can effectively inhibit the growth of the virus in the early stages of the disease,
- while remdesivir, also manufactured in Hungary and licensed in the United States and the European Union, is effective in treating patients requiring hospitalization.
Favipiravir is a broad spectrum antiviral agent. Formulations containing this have been shown to be effective against new coronavirus infection in several studies, and more are in progress, including that developed by the Hungarian consortium, the drug researcher’s telegraph office cites.
The drug has been used in influenza infection in various clinical trials and has been administered to hundreds of thousands of coronavirus patients around the world. There have been few and mild side effects from the treatments, however the drug should not be used during pregnancy.
However, there is an important condition for using favipiravir:
As the active substance inhibits the growth of the virus, it can only be used most successfully in the first phase of the disease, within 7 to 10 days after the onset of symptoms.
With the intensification of the epidemic and the reduction of hospital capacity, the chances of patients receiving this treatment in this early phase of infection are decreasing, as products containing favipiravir are currently only used in hospitals, citing Miklós György Keserű MTI.
The promising positive experience gained so far in clinical and home care gives people with symptoms the opportunity to increase the risk of coronavirus infection, even in primary care, that is, outside the hospital. Not only can this option be a solution for the patient, but early intervention can also relieve hospitals of the burden, said a participant from the Coronavirus Research Task Force.
[ad_2]
